Assenagon Asset Management’s Standard BioTools LAB Stock Holding History

Assenagon Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-417,917	Closed	-$740K	–	1418
2024 Q2	$740K	Sell	417,917 -160,522	-28%	-$392K	﹤0.01%	1169
2024 Q1	$1.57M	Buy	578,439 +512,937	+783%	+$1.24M	﹤0.01%	957
2023 Q4	$145K	Buy	+65,502	New	+$140K	﹤0.01%	1380
2021 Q2	–	Sell	-674,525	Closed	-$3.05M	–	1313
2021 Q1	$3.05M	Buy	674,525 +37,772	+6%	+$207K	0.01%	612
2020 Q4	$3.82M	Sell	636,753 -477,477	-43%	-$3.14M	0.02%	410
2020 Q3	$8.28M	Sell	1,114,230 -30,998	-3%	-$214K	0.05%	226
2020 Q2	$4.59M	Buy	1,145,228 +669,763	+141%	+$2.33M	0.03%	345
2020 Q1	$1.21M	Buy	+475,465	New	+$1.56M	0.01%	477
2019 Q4	–	Sell	-208,730	Closed	-$966K	–	856
2019 Q3	$966K	Buy	208,730 +103,330	+98%	+$814K	0.01%	563
2019 Q2	$1.3M	Buy	+105,400	New	+$1.34M	0.01%	650

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's LAB Position: Q3 2024 in Review

Assenagon Asset Management sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 417,917 shares — an estimated $740K sold.

Assenagon Asset Management first reported a position in LAB in Q2 2019 and held it in 10 quarters. The position peaked at $8.28M in Q3 2020. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Assenagon Asset Management reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Assenagon Asset Management sold 417,917 Standard BioTools shares in Q3 2024, an estimated $740K.
Assenagon Asset Management first reported a position in Standard BioTools in Q2 2019 and held it in 10 quarters.
Assenagon Asset Management's Standard BioTools position peaked at $8.28M in Q3 2020.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Assenagon Asset Management's 13F filing for Q3 2024, filed 23 Oct 2024.